[Pulmonary affection in advanced liver disease - hepatepulonary syndrome and portopulmonary hypertension].

Med Klin (Munich)

Zentrum für Innere Medizin, Gastroenterologie und Hepatologie, Essen, Germany.

Published: December 2010

Patients suffering from severe chronic liver disease, in particular cirrhosis, are at risk for pulmonary complications. The leading clinical symptom is shortness of breath, which can accompany the actual disease as indirect effect because of anemia, faint muscles or ascites. On the other hand, dyspnea can have multiple additive causes in case of accompanying cardial or pulmonary disease. The hepatopulmonary syndrome (HPS) and the portopulmonary hypertension (PoPH) belong to the most relevant pulmonary complications in liver cirrhosis. HPS appears to be more common than PoPH and the presence of either entity increases morbidity and mortality in patients with liver disease. The two diseases have to be strictly distinguished, as they have opposed histological and pathophysiological origin. While the HPS is a dilatative pulmonary- vascular disease, the PoPH is a constrictive or obliterative pulmonary-vascular disease in the context of a liver disease or a portal hypertension. Therefore, these diseases are separate entities also when it comes to diagnostics and therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00063-010-1157-9DOI Listing

Publication Analysis

Top Keywords

liver disease
16
disease
8
pulmonary complications
8
liver
5
[pulmonary affection
4
affection advanced
4
advanced liver
4
disease hepatepulonary
4
hepatepulonary syndrome
4
syndrome portopulmonary
4

Similar Publications

Background And Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) and its more severe subtype, metabolic dysfunction-associated steatohepatitis (MASH), are highly prevalent and strongly associated with obesity and type 2 diabetes (T2D). This study sought to identify challenges to the diagnosis, treatment and management of people living with MASLD and MASH and understand the key barriers to adopting relevant clinical guidelines.

Methods: A real-world, cross-sectional study (BARRIERS-MASLD) consisting of a quantitative survey and qualitative interviews of physicians in France, Germany, Italy, Spain and the United Kingdom was conducted from March to September 2023.

View Article and Find Full Text PDF

With complex pathogenesis, Alzheimer's disease (AD) is a neurological illness that has worsened over time. Inter-organ crosstalk, which is essential for coordinating organ function and maintaining homeostasis, is involved in multiple physiological and pathological events. Increasing evidence suggests that AD is closely associated with multiple diseases of peripheral organs, including the gut, adipose tissue, liver, and bone.

View Article and Find Full Text PDF

The exclusion of cirrhosis is important in chronic hepatitis B (CHB) patients with normal alanine aminotransferase (ALT). We aimed to optimise the performance of the aspartate aminotransferase to platelet ratio index (APRI) and fibrosis score based on four factors (FIB-4) to exclude cirrhosis in these patients. Five hundred and eighty four patients with normal ALT who underwent liver biopsy were included in the study.

View Article and Find Full Text PDF

For the first time, a TiCT-MXene and poly (3, 4-ethylenedioxythiophene): poly (styrenesulfonate) (PEDOT: PSS) composite-modified electrode has been developed for electrochemical detection of the bilirubin (BR) by molecularly imprinted ortho-phenylenediamine (o-PD). BR is a biomarker for liver-related diseases. High levels of BR imply liver dysfunction; hence, its exact and rapid measurement is indispensable to its immediate diagnosis and treatment.

View Article and Find Full Text PDF

Background: Progranulin (PGRN) haploinsufficiency is a major risk factor for frontotemporal lobar degeneration with TDP-43 pathology (FTLD-GRN). Multiple therapeutic strategies are in clinical development to restore PGRN levels in the CNS, including gene therapy. However, a limitation of current gene therapy approaches aimed to alleviate FTLD-associated pathologies may be their inefficient brain exposure and biodistribution.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!